Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
As Your Serene Highness well knows, I discovered in the heavens many things that had not been seen before our own age. The novelty of these things, as well as some consequences which followed from them in contradiction to the physical notions commonly held among academic philosophers, stirred up against me no small number of professors—as if I had placed these things in the sky with my own hands in order to upset Nature and overturn the sciences. They seemed to forget that the increase of known truths stimulates the investigation, establishment, and growth of the arts; not their diminution or destruction. (Galileo's Daughter, Dava Sobel, Walker & Company, New York, NY, U.S.A., 1999.) For over five decades, osteoporotic fractures have been recognized as one of the most devastating complications of chronic treatment with corticosteroids. However, until now, the relationship between the dose and duration of oral glucocorticoid use and the risk of fractures or the effect of discontinuing treatment on subsequent risk were unknown. In this issue, van Staa and coworkers report the results of a retrospective cohort study involving an astounding number of a quarter of a million oral steroid users and an equal number of age and sex-matched control patients from a computerized medical record database of general practitioners in the United Kingdom.1 They show that the risk of fractures, especially for the vertebrae and the proximal femur, increases in direct proportion with the daily dose of the steroid. This observation could be reasonably anticipated. However, what is completely unexpected is the finding that the fracture risk increases rapidly (as early as 3 months) after the initiation of steroid therapy. And, even more strikingly, it reverses sharply after the discontinuation of the medication toward baseline, although it does not reach it. The sheer size of the population studied by van Staa et al.1 makes it unlikely that a similar source of information will be available any time soon. Therefore, I fully expect that the findings of this study and their theoretical and practical implications will reverberate in the field for some time. I welcome the opportunity to give my perspective and get the debate going. The retrospective design of the study has, of course, the usual limitations and potential pitfalls, which van Staa et al.1 appropriately recognize and discuss, but these hardly detract from the validity of the observations. Bone mineral density (BMD) values apparently are not available for this large epidemiological analysis. Albeit, I doubt that these rapid changes in fracture incidence could be explained away by corresponding changes in BMD or even true bone mass because they seem to occur long before bone mass could have been lost or restored to such an extent as to alter bone strength as drastically as the results indicate. The contention that changes in bone mass alone cannot explain the rapid onset and offset of fractures in this study is supported by observations that the incidence of fractures is higher in patients with corticosteroid-induced osteoporosis than postmenopausal or involutional osteoporosis, even though BMD is relatively higher in the former.2-4 Furthermore, there is abundant evidence for an incongruity between BMD and fractures from numerous studies showing that the antifracture efficacy of traditional therapies for osteoporosis, for example, estrogen, bisphosphonates, and calcitonin, is far greater than the BMD changes produced by these agents.5 This incongruity holds even when one takes into consideration the fact that the relationship of BMD and fractures is a power function. Taken together with the results of van Staa et al.1 all these lines of evidence challenge traditional ideas about the mechanisms leading to increased fragility in osteoporosis, the relationship between bone mass and fractures, or our ability to predict fracture risk by conventional means. van Staa et al.1 offer three explanations for their findings: the apoptosis of osteoblasts and osteocytes induced by corticosteroids; a marked alteration (I suspect they mean an increase) in bone turnover, through induction of microarchitectural changes in bone quality; and nonskeletal mechanisms like increased risk of falling. I will address the last one first. Unquestionably, falls play a very important role in osteoporotic fractures in general and may indeed contribute to the rapid onset and offset of fracture risk in the analysis of this report. However, I seriously doubt that falls alone can account for these findings, especially because vertebral as well as nonvertebral fractures exhibit practically identical time kinetics and forearm is the site affected least. Van Staa et al.1 suggest that marked alteration in bone turnover is in agreement with the evidence of a protective effect of bisphosphonates in corticosteroid-induced osteoporosis. This is in my opinion unconvincing, if not outright erroneous. Turnover in corticost
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 1×
“(7) Conversely, preservation of the osteocyte network seems to be an important mechanism by which bisphosphonates, calcitonin and estrogen replacement therapy decrease bone fragility.”
BackgroundSelf-citationUse of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 2×
“((15,21,22))Moreover, inhibition of osteoblast and osteocyte apoptosis is the most likely mechanism of the anabolic effect of i termittent PTH therapy; and, in fact, prevention of teoblast (and osteocyte) apoptosis predictably leads to more numerous and closely spaced osteocytes.”
BackgroundSelf-citationHofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Verborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731
Identification of apoptotic changes in osteocytes in normal and pathological human bone
Noble, B. S., Stevens, H., Loveridge, N., & Reeve, J. (1997) · Bone · doi:10.1016/s8756-3282(96)00365-1 · Cited by 230
Cited by
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
“Although their precise function is unknown, apoptosis could lead to a deterioration of bone quality and early increases in fracture risk [127].”
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
Self-citationA meta-analysis of prior corticosteroid use and fracture risk.
Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, L. J., Tenenhouse, A., Reeve, J., Silman, A. J., Pols, H. A., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040134 · Cited by 839
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Self-citation
Metadata
- Authors
- Manolagas, S. C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-06-01
- Volume
- 15
- Issue
- 6
- Pages
- 1001-1005
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1982234235
- Cited by
- 135
- References
- 6
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind. https://app.cochat.ai/papers/10.1359/jbmr.2000.15.6.1001
- The paper
- Manolagas, S. C. (2000). Corticosteroids and Fractures: A Close Encounter of the Third Cell Kind. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.2000.15.6.1001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.